Rock Creek Advisors (the “Sale Agent”) is contacting you regarding Molecular Templates, Inc. (the “Company” or “Molecular Templates”) (NASDAQ: MTEM). We are helping sell the Company and/or Assets to a strategic partner or financial buyer who can work to develop and commercialize the assets to a successful completion. The assets include intellectual property, licenses, trademarks, know-how, and PP&E.
Molecular Templates is a clinical-stage biotechnology company focused on discovering and developing novel biologic therapeutics. MTEM specializes in developing Engineered Toxin Bodies (ETBs), a next-generation biologic platform designed to treat cancer and other diseases. The Company’s technology harnesses the unique biological properties of a proprietarily engineered de-immunized bacterial toxin scaffold to create targeted therapies with novel mechanisms of action that induce tumor cell death.
Molecular Templates, Inc. (MTEM) is advancing several promising programs, including MT-0169, MT-6402, and MT-8421. MT-0169 is a lead candidate with a potent mechanism of cell-kill against CD38+ immune cells. MT-0169 has shown safety and efficacy in a small phase I study in relapsed or refractory multiple myeloma where it also demonstrated deep depletion of CD38+ immune cells. MT-0169 can be rapidly advanced into the autoimmune setting where its unique mechanism of action (direct cell-kill via ribosome inhibition) may result in better immune cell clearance than antibody approaches.
Investment Highlights
- Innovative Platform Technology: MTEM’s Engineered Toxin Bodies act through novel mechanisms of action represent a breakthrough in cancer treatment by providing targeted, direct cell-killing mechanisms that do not rely on high receptor expression or the presence of effector cells.
- Validated Clinical Potential: Over 100 patients have been treated with MTEM’s de-immunized ETBs across multiple clinical programs with no occurrences of capillary leak syndrome (CLS), which is often seen with similar immunotoxin therapies.
- Diverse Clinical Pipeline: The Company is targeting high-value markets within oncology and autoimmune disease. MT-0169 represents a potentially novel approach with superiority over current modalities targeting CD38 for a variety of autoimmune indications. MT-6402 and MT-8421 are unique approaches to immuno-oncology focused on immune cell depletion in the tumor microenvironment to restore T cell potency against tumors. Both programs have demonstrated promising signals of anti-tumor activity in Phase 1 studies.
- Growth Potential: The global cancer treatment market is rapidly expanding, and MTEM’s cutting-edge technology positions it to capture significant value as new treatments progress through the pipeline.
- Strong IP Portfolio: MTEM holds robust intellectual property protections around its ETB platform, safeguarding its technological innovations and ensuring long-term competitive advantages.
See Teaser linked below for information on the Company, its products, IP and clinical information, and leadership team.
Final Term Sheet Deadline: Tuesday, November 26th, 2024, 5pm ET
While the Company may give preference to all-cash bids, Rock Creek will consider all types of consideration.
We require an executed Confidentiality Agreement (see NDA link below) and satisfactory evidence of financial wherewithal to provide access to a Confidential electronic data room with more Company information.
If there is another person at your firm who would be more appropriate to review this matter, please let us know and/or forward this information accordingly. Also, if your firm is not interested in pursuing this opportunity, we’d appreciate knowing in order not to continue to follow up with you.